ENFOQIS

Serial Number 88783014
606

Registration Progress

Application Filed
Feb 3, 2020
Under Examination
Mar 2, 2021
Approved for Publication
Jan 5, 2021
Published for Opposition
Jan 5, 2021
Registered

Basic Information

Serial Number
88783014
Filing Date
February 3, 2020
Published for Opposition
January 5, 2021
Abandonment Date
April 8, 2024
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Apr 8, 2024
Classes
005

Rights Holder

Cingulate Therapeutics LLC

16
Address
1901 W 47th Place, Suite 310
Kansas City, KS 66205

Ownership History

Cingulate Therapeutics LLC

Original Applicant
16
Kansas City, KS

Cingulate Therapeutics LLC

Owner at Publication
16
Kansas City, KS

Legal Representation

Attorney
Susan Neuberger Weller

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

44 events
Date Code Type Description
Apr 8, 2024 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Apr 8, 2024 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 8, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 7, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 7, 2023 EX5G S SOU EXTENSION 5 GRANTED
Aug 28, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Aug 28, 2023 EXT5 S SOU EXTENSION 5 FILED
Feb 16, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 14, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 14, 2023 EXT4 S SOU EXTENSION 4 FILED
Feb 14, 2023 EX4G S SOU EXTENSION 4 GRANTED
Jan 17, 2023 DOCK D ASSIGNED TO EXAMINER
Aug 25, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 23, 2022 EEXT I SOU TEAS EXTENSION RECEIVED
Aug 23, 2022 EXT3 S SOU EXTENSION 3 FILED
Aug 23, 2022 EX3G S SOU EXTENSION 3 GRANTED
Feb 24, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 22, 2022 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 22, 2022 EXT2 S SOU EXTENSION 2 FILED
Feb 22, 2022 EX2G S SOU EXTENSION 2 GRANTED
Jul 20, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 20, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 20, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 8, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 4, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 4, 2021 EXT1 S SOU EXTENSION 1 FILED
Jun 4, 2021 EX1G S SOU EXTENSION 1 GRANTED
Mar 2, 2021 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 5, 2021 PUBO A PUBLISHED FOR OPPOSITION
Jan 5, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 16, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 2, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 23, 2020 ALIE A ASSIGNED TO LIE
Nov 23, 2020 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 21, 2020 CNEA R EXAMINERS AMENDMENT -WRITTEN
Apr 21, 2020 GNEA F EXAMINERS AMENDMENT E-MAILED
Apr 21, 2020 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 21, 2020 XAEC I EXAMINER'S AMENDMENT ENTERED
Apr 21, 2020 CNSL R SUSPENSION LETTER WRITTEN
Apr 21, 2020 GNSL S LETTER OF SUSPENSION E-MAILED
Apr 21, 2020 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 20, 2020 DOCK D ASSIGNED TO EXAMINER
Feb 6, 2020 NWAP I NEW APPLICATION ENTERED
Feb 6, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder (ADHD)
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005